Renal cell carcinoma (RCC) is a major health issue. Whereas localized disease can be cured surgically, there is no effective therapy for metastatic disease. The development of an effective therapy will require an understanding of the pathways that are important in RCC carcinogenesis and progression. Using genomic profiling of patientmatched tissue, we have identified aberrations in the transforming growth factor b (TGFb) signaling pathway in RCC. We observed loss of type III TGFb receptor (TBR3) expression in all RCC samples. This suggests that TBR3 loss is an early event in RCC carcinogenesis and plays a sentinel role in the acquisition of a tumorigenic phenotype. We also observed subsequent loss of type II TGFb receptor (TBR2) expression in metastatic RCCs. We propose that loss of TBR3 is necessary for RCC carcinogenesis, and that loss of TBR2 leads to acquisition of a metastatic phenotype. To this end, we have identified a human renal cell carcinoma line (UMRC6) that is representative of localized, nonmetastatic RCC, reflecting a loss of TBR3, but not TBR2 expression. Another cell line, UMRC3, is highly metastatic, having lost TBR3 and TBR2 expression. We demonstrate functional loss of TGFb responsiveness in these cell lines as observed through phenotypic and transcriptional responsiveness to exogenous TGFb. Restoring TBR2 and TBR3 expression in UMRC3 cells attenuates cell proliferation, completely restores TGFb-mediated transcriptional responses, and completely blocks anchorage independent-growth: while restoration of TBR2 partially restores TGFb-mediated signaling. Based on these data, we propose that dysregulation in TGFb signaling, through stepwise loss in receptor expression, plays a prominent role in RCC carcinogenesis and progression. In addition, these studies unequivocably demonstrate a link between loss of TBR3 and a human disease.
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Introduction
Renal cell carcinoma (RCC) represents a major health issue. The American Cancer Society predicts 31 900 new cases diagnosed in the United States alone in the year 2003, with 11 900 people dying of the disease (Jemal et al., 2003) . When clinically localized or even locally advanced, RCC can be surgically resected for cure using a variety of approaches. With metastatic progression, however, RCC is incurable, and existing systemic therapies are largely ineffective in impacting disease response or patient survival. The lack of effective systemic therapy for metastatic RCC is, in part, due to a fundamental lack of understanding of the molecular events that result in cellular transformation, carcinogenesis, and progression in the human kidney. With further studies that identify molecular pathology associated with renal cell carcinogenesis and progression, targeted therapy that specifically impacts signal transduction pathways important in RCC can be developed.
The advent of gene array technology (Schena et al., 1995; DeRisi et al., 1996) has allowed the classification of disease states at the molecular level by examining changes in all mRNAs expressed in cells or tissues. We used gene array technology to analyse signal transduction pathways in conventional RCC. We compared patterns of gene expression between normal renal epithelium, nonmetatastic RCC, and primary and disseminated lesions in metastatic RCC. Through these studies, we have identified a variety of gene expression alterations in many signal transduction pathways important in cellular homeostasis, including genes that are integral to transforming growth factor b (TGFb) signal transduction. TGFbs are potent, pleiotropic cytokines involved in essential cellular functions, reg-ulating cellular proliferation, differentiation, apoptosis, development, tissue repair, cell motility, extracellular matrix (ECM) formation, inflammation, immunosuppression, and tumorigenesis. TGFb interacts with two signaling TGFb receptors (TBR), called type I (TBR1) and type II (TBR2). TBR2 is thought to bind to TGFb with high affinity and to recruit and activate TBR1, which then signals downstream through one or more effectors, of which the Smads are the best understood examples (reviewed in Derynck et al., 1998; Gold, 1999; Massague and Wotton, 2000) .
A third receptor exists, for which little signaling function is known, called the type III receptor (TBR3) or betaglycan. TBR3 is an 853 amino-acid transmembrane proteoglycan with a small, serine-rich cytoplasmic domain of 41 amino acids (Lopez-Casilas et al., 1991) . It has been proposed that TBR3 controls the access of TGFbs to the signaling receptors, TBR2 and TBR1 (Laiho et al., 1990) . TBR3 is the most abundant TBR in cells and has higher affinity for TGFb2 and similar affinity for TGFb1 and TGFb3, when compared to TBR2 (Boyd and Massague, 1989) . TBR3 possesses two extracellular ligand-binding domains, capable of binding TGFb independently (Esparza-Lopez et al., 2001) .
In this investigation, we studied alterations in TBR expression and TGFb-regulated genes that were found in our gene array analysis of localized and metastatic RCC: using cell models relevant to clinically staged RCC. Based on these data, we hypothesized that alterations in TGFb signaling through aberrations in receptor expression may play an important role in RCC biology. Specifically, we identified that loss of TBR3 was an early event in RCC carcinogenesis and that subsequent loss of TBR2 was associated with acquisition of a metastatic phenotype. These findings represent an association between sequential loss of TBR expression and RCC carcinogenesis and progression, and demonstrate an association between loss of TBR3 expression and a unequivocal human disease.
Results

Loss of TBR expression demonstrated by gene array and real-time PCR in RCC
We performed gene expression profiling using Affymetrix HU95A oligonucleotide gene arrays (412 600 genes). RNA was extracted from patient-matched normal renal cortical and tumor tissues from patients diagnosed with localized and metastatic RCC. Data were analysed by a combination of two-dimensional ANOVA, Affymetrix MAS5.0, and hierarchical cluster analysis using Spotfire (reviewed in Copland et al., 2003) . A primary goal of microarray analysis is to discover hidden patterns of differential expression within a large data field. Normal renal cortical and primary tumor tissue with no metastasis were collected from each of five patients diagnosed with local disease. We also collected normal tissue, primary tumor, and metastatic tissue from each of five patients diagnosed with metastatic disease. Comparison of patient-matched normal and tumor tissue allowed for the discovery of changes in mRNA levels between normal and tumor tissue, as well as local and metastatic disease. We expected that if a key signaling pathway were altered, then multiple genes regulated by that pathway would be affected.
One such pathway that we have identified determines responsiveness to TGFb through TBR expression. Pertinent data are summarized in Figure 1 , in which expression of TBR1, TBR2, or TBR3 mRNA is compared in normal renal tissue, primary RCC without metastasis, primary lesions of metastatic RCC, and metastatic lesions. In Figure 1a , which represents a summary of our gene array analysis, average signal intensities are shown (mean7standard error). The signal intensity for TBR1 (cross-hatched bars) was relatively low, although TBR1 was scored as 'Present' in all samples. No significant changes in TBR1 expression were observed. TBR2 (gray bars) was abundantly expressed in normal epithelium and in primary lesions of nonmetastatic RCC. We noted that TBR2 was significantly reduced in primary lesions with metastatic disease (Po0.028 by ANOVA). TBR2 was even more reduced in metastatic lesions. TBR3 expression was high in normal epithelium, but was significantly reduced in each of the five primary tumors with nonmetastatic disease (black bars). TBR3 expression was also reduced in primary tumors with metastatic lesions and in metastatic lesions themselves.
These expression patterns were confirmed by real-time PCR (Taqman s ) in the 10 patients used for our gene array analysis. Means and standard errors for individual samples are shown in Figure 1b . All data were normalized to 18S rRNA and calibrated to target abundance in the paired normal tissues. TBR1 mRNA abundance did not change (cross-hatched bars), consistent with the gene chip data. TBR2 (gray bars) was not reduced in primary tumors without metastases, whereas TBR2 was significantly reduced in primary tumors with metastatic disease and in metastatic lesions. TBR3 was reduced in all tumors (black bars). We have subsequently completed real-time PCR analysis of TBR1, TBR2, and TBR3 expression in 16 primary tumors without metastases (plus paired normal epithelium) and nine samples of primary tumors with metastatic disease, paired metastatic lesions, and paired normal tissue. The data were consistent with those shown for the samples analysed in Figure 1a . TBR3 expression was significantly reduced in all tumors; whereas TBR2 expression was reduced in only 1/16 primary tumors without metastatic lesions, but was reduced in primary tumors with metastatic lesions (8/9). Our data show that loss of TBR3 is an early event in RCC, strongly suggesting that TBR3 plays a critical role in RCC carcinogenesis. We have correlated loss of TBR3 mRNA expression with TNM scores (T, tumor N, lymph node; M, metastasis) from patient samples (data not shown). TBR3 mRNA expression is suppressed in the earliest stage, stage I, and is found to be suppressed in all tumor stages (I-IV). In addition, loss of TBR2 in the primary tumor is significantly associated with acquisition of the metastatic phenotype and clinically manifests as metastatic progression.
TGFb receptor expression and activity in human RCC
Decreased TBR3 mRNA expression in all tumors was associated with failure to detect TBR3 protein by immunohistochemistry, as shown in Figure 2 . TBR2 protein was detected in localized tumor (primary, no mets), but was not detectable in primary tumors with metastatic disease or in corresponding metastatic lesions ( Figure 2 ). TBR1 protein was detected in normal tissue and in all tumor samples. We hypothesized that these losses seen in TBR expression would manifest as an attenuation of TGFb-mediated signal transduction, and would significantly alter the expression of TGFbregulated genes.
We have identified, from our gene array data, 13 known TGFb/Smad-regulated genes that are downregulated in RCC (Table 1) . Using mRNA from 35 patient-matched samples, we verified loss of expression of three of these genes by comparing matched normal and tumor tissue. As shown in Figure 3 , real-time PCR was used to measure the expression of Collagen IV type 6, fibulin-5, and connective-tissue growth factor (CTGF). Collagen IV type 6 (gray bars) is an ECM protein that plays a critical role in the regulation of membrane integrity and cell signaling (Gilbert et al., 1998; Wogensen et al., 1999) . Fibulin-5 is a recently discovered TGFb-regulated gene, which has tumor suppressor activity. Fibulin-5 is an ECM protein that is believed to signal through interaction with integrins (Schiemann et al., 2002) . CTGF is a secreted protein involved in angiogenesis, skeletogenesis, and wound healing. CTGF enhances TGFb1 binding to TBR2, and CTGF and TGFb collaborate to regulate the expression of ECM proteins during renal fibrosis (Sakharova et al., 2001; Abreu et al., 2002) . As summarized graphically in Figure 3 , all the TGFb-regulated genes we evaluated were downregulated in early tumor stages, suggesting that RCC undergoes loss of TGFb responsiveness at an early stage. Our data indicate that this loss of TGFb sensitivity is due, primarily, to loss of TBR3 in early tumor development and further loss of sensitivity in metastatic disease is mediated through subsequent loss of TBR2.
TGFb receptor expression in RCC cell lines
We identified human RCC cell lines that recapitulate our clinical observations of TBR biology. UMRC6 cells were derived from a clinically localized human RCC (Grossman et al., 1985) . As shown in Figure 4a , UMRC6 cells express TBR2 mRNA, but not TBR3. Immunohistochemical analysis (Figure 4b ) confirms the presence of TBR2 protein and the absence of TBR3 expression. UMRC3 cells were derived from the primary tumor of a patient with metastatic RCC. This highly aggressive cell line lacks detectable TBR2 and TBR3 mRNA ( Figure 4a ) and protein ( Figure 4b ). In addition Mucin 1 1q21 6.5
As described in materials and methods Section, data were analysed by a combination of two-dimensional ANOVA, Affymetrix MAS5.0, and hierarchical cluster analysis using Spotfire to identify genes that are downregulated in local tumors versus that of normal renal cortex tissue. The gene names and corresponding GenBank number and chromosome location are listed to these relevant laboratory models, we harvested normal renal epithelial (NRE) tissue from nephrectomy specimens and established them as primary cultures (Trifillis, 1999) . As shown in Figure 4a and b, these primary cultures of NRE express TBR3, TBR2, and TBR1 mRNA and protein in vitro. NRE cells can be grown in culture for 10 passages and are easily isolated and characterized (Sens et al., 1999; Trifillis, 1999) . We characterized NRE cells for cytokeratin expression and tubule-specific gene expression, for example, megalin [(data not shown; (Dedir et al., 1996; Trifillis, 1999; Terzi et al., 2000) ]. Thus, we have relevant cell models in which TBR2 and TBR3 expression can be manipulated to examine the impact of TBR biology on human RCC carcinogenesis and progression, in vitro.
TGFb activity in RCC cell lines
It is well known that TGFb1 inhibits cell proliferation in epithelial cells. As shown in Figure 5a (squares), TGFb1 inhibited the proliferation of NRE cells in culture.
URMC3 cells express neither TBR2 nor TBR3 and, not surprisingly, are resistant to the inhibitory effects of TGFb on cell proliferation (triangles, Figure 5a ). UMRC6 cells express TBR2, but not TBR3, and are partially resistant to TGFb1 (circles, Figure 5a ). We also measured TGFb transcriptional activity in our cell models using transient transfection of the 3TP/ lux reporter, which contains 3AP-1/and one Smad3 response elements, from the PAI-1 promoter (a gift from Dr Joan Massague). This luciferase reporter construct demonstrates increased transcriptional activity in response to exogenous TGFb-mediated signal transduction. As shown in Figure 5b , NRE cells are highly responsive to 2 ng/ml (80 pM) TGFb1. UMRC6 demonstrates significantly less luciferase activity in response to TGFb1, and UMRC3 cells are entirely unresponsive.
Recapitulation of TGFb signaling through reintroduction of TBR expression into RCC
To test whether reintroduction of TBR expression would result in re-establishment of TGFb signal transduction and reacquisition of TGFb cellular sensitivity, we engineered UMRC3 cells to express either TBR2 ( þ TBR2) alone or TBR2 plus TBR3 ( þ TBR2 þ TBR3) stably. As shown in Figure 6a , stable transfection of TBR2 alone or TBR2 þ TBR3 resulted in detectable levels of mRNA for each receptor on RT-PCR analysis. On examining the in vitro growth kinetics of these re-engineered cells, we noted that reintroduction of TBR2 resulted in a twofold reduction in cell proliferation and reintroduction of both TBR2 and TBR3 resulted in a fourfold reduction in cell proliferation with the addition of exogenous TGFb1.
We then examined TGFb-mediated transcriptional activity as a consequence of TBR re-expression. As shown in Figure 6b , reintroduction of TBR2 partially restored transcriptional responsiveness, as evidenced by a 5.6-fold increase in 3TP/lux activity after the addition of TGFb1. Reintroduction of both TBR2 and TBR3 into UMRC3 cells resulted in 17.5-fold increase in 3TP/ lux activity after the addition of TGFb1. To demonstrate re-establishment of TGFb-regulated gene expression, we examined collagen IV type 6 mRNA expression using real-time PCR in our re-engineered cell lines in the presence of TGFb1. As shown in Figure 6c , reexpression of TBR2 in UMRC3 cells ( þ TBR2) results in a sevenfold increase in collagen IV type 6 mRNA levels over that of UMRC3 controls, while reintroduction of both TBR2 and TBR3 enhanced collagen IV type 6 mRNA expression 11-fold. These data are consistent with a number of published reports that indicate that expression of TBR3 is essential for full TGFb responsiveness (Blobe et al., 2001; Esparza-Lopez et al., 2001 ).
UMRC3 cells have been shown to be tumorigenic in athymic nude mice (Grossman et al., 1985) . Anchorageindependent growth in soft agar is a well-established in vitro correlate of in vivo tumorigenicity. As shown in Figure 6d , UMRC3 cells demonstrated anchorage- independent growth in soft agar. Reintroduction of TBR2 into UMRC3 cells significantly decreased the number and size of colonies that formed in soft agar. Reintroduction of both TBR2 and TBR3 completely abrogated the ability of UMRC3 cells to form colonies in soft agar, even after 45 days in culture. These data demonstrate that reintroduction of TBR2 resensitizes UMRC3 cells to the effects of exogenous TGFb through reacquisition of TGFb signal transduction. More interestingly, however, we found that reintroduction of TBR3 in the presence of TBR2 into UMRC3 cells significantly enhanced TGFb-regulated gene transcription, growth inhibition, and loss of anchorage-independent growth over that seen with reintroduction of TBR2 alone. These data clearly show that RCC tumor cells are TGFb resistant. Loss of TBR3 expression occurs early and appears to be associated with a relatively less aggressive state that is partially TGFb responsive. Loss of TBR2 results in frank TGFb resistance and is associated with acquisition of a more aggressive phenotype.
Discussion
Through the use of genomic profiling in human RCC, we have demonstrated the stepwise sequential loss of TBR3 and TBR2 expression in association with renal cell carcinogenesis and progression. These findings were subsequently confirmed using both immunohistochemistry and real-time PCR in patient-matched tissue samples. We then brought this clinical observation to the laboratory and identified relevant in vitro models. Using these models, we then demonstrated that loss of TBR3 expression resulted in incremental desensitization to TGFb and attenuation of TGFb signaling. Subsequent loss of TBR2 resulted in complete loss of TGFb sensitivity. With in vitro modulation of TBR expression, we demonstrated reconstitution of the TGFb signaling pathway, which resulted in significant growth inhibition and loss of the aggressive phenotype.
These experiments are unique in that we have taken clinically relevant observations, derived from the evaluation of gene expression in normal renal cortical tissue, localized RCC, and metastatic RCC, and then brought these observations to the laboratory for validation and experimental manipulation in relevant Figure 6 UMRC3 cells stably transfected with TBR2 or TBR2 þ TBR3 regain TGFb responsiveness. (a) UMRC3 þ TBR2 and UMRC3 þ TBR2 þ TBR3 stable cell lines demonstrate attenuated cell proliferation following the administration of exogenous TGFb1 as compared to that for UMRC3 cells. The inset demonstrates RT-PCR-derived mRNA expression of TBR3, TBR2, and TBR1 in UMRC3 cells and cells stably transfected with TBR2 and TBR3. (b) UMRC3, UMRC3 þ TBR2, and UMRC3 þ TBR2 þ TBR3 stable cell lines transfected with 3TP/ lux were treated with and without TGFb and examined for luciferase activity as described previously. (c) Real-time PCR measuring mRNA levels for collagen IV type 6 in UMRC3, UMRC3 þ TBR2 ( þ TBR2), and UMRC3 þ TBR2 þ TBR3 ( þ TBR2 þ TBR3) cells in the presence of 2 ng/ml TGFb1 for 24 h. (d) A colony formation assay demonstrates that UMRC3 þ TBR2 ( þ R2) þ TBR3 ( þ R3) have completely lost anchorage-independent growth, while attenuated growth in UMRC3 þ TBR2 occurs as compared to that of UMRC3 cells. The number of colonies were stained and counted after 45 days of growth. Data are expressed as mean7s.d. in vitro models. Other investigators have examined human RCC lines and identified alterations in the expression of TGFb signaling pathway intermediaries such as TBR2 and the Smads (Engel et al., 1999) , but these observations have not been validated in the clinical biology of RCC. Ramp et al. (1997b) found that TBR3 mRNA was expressed in only 1/13 RCC cell lines examined. To our knowledge, few studies have methodically examined the expression of all three TBRs in patient samples at the protein and mRNA level, in an effort to correlate TBR expression to disease-specific states of RCC (i.e. localized versus metastatic tumor). A major strength of the present study is that we recognized distinct disease states in RCC biology, associated them with specific alterations in the TGFb signaling pathway, and then validated and manipulated our clinical observations in the laboratory.
In epithelial cells, the effect of TGFb is generally to inhibit proliferation, promote cellular differentiation, and regulate interactions with the ECM. TGFb can suppress as well as activate the transcription of defined target genes. Transcriptional activation by Smads, intermediaries in TGFb signal transduction, has been studied in some detail (reviewed in Maustakas et al., 2001) . There is evidence that TGFb can signal through pathways that do not require Smads, as well as through pathways in which Smads function through interactions with other signaling pathways, including NF-kB, MAP kinases, and the b-catenin/TCF pathway (reviewed in Zhang and Derynck, 1999; ten Dijke et al., 2000) . Although the mechanisms are not well understood, it is clear that TGFb regulates a large number of diverse biological functions, including cell proliferation, differentiation, cell adhesion, apoptosis, ECM production, immune regulation, neuroprotection, and early embryonic development. As a direct consequence, aberrations in TGFb signaling can have a dramatic impact on cellular processes that are critically associated with neoplastic and malignant transformation. This relationship has been studied in most detail in colon cancer, in which it was first recognized that loss of TGFb responsiveness was associated with the transition from adenoma to carcinoma (Kinzler and Vogelstein, 1996) . Hereditary nonpolyposis colorectal carcinoma is associated with loss-of-function mutations to TBR2 (Markowitz et al., 1995) , and a recent survey indicates that loss of TBR2 expression occurs in about 85% of all colon cancers (reviewed in Kim et al., 2000; Akhurst and Derynck, 2001) . Alterations in TGFb signaling have also been implicated in RCC. Lee and colleagues demonstrated loss of TBR2 expression in an aggressive murine model of RCC and that re-expression of TBR2 abrogated the aggressive phenotype (Kundu et al., 1998; Engel et al., 1999) . Others have demonstrated downregulation of TBRs in human RCC cell lines and resistance to TGFb, again implicating alterations in TGFb signaling, mediated through alterations in receptor expression, as important events in RCC biology (Ramp et al., 1997a) . None of these studies, however, have critically evaluated the role of TBR3 expression in renal cell carcinogenesis and progression.
Given the well-documented observation that the end result of TGFb signaling is largely growth inhibitory, it makes intuitive sense that the cancer cell would develop mechanisms to escape TGFb sensitivity. To date, these mechanisms have not been elucidated in human RCC. Interestingly, it has been reported that human RCCs overexpress TGFb1 and that levels of TGFb1 are elevated in the serum of patients with RCC (Cardillo et al., 2001; Hegele et al., 2003) . In these reports, the authors hypothesized that TGFb1 overexpression may be an important mediator of tumor-derived immunosuppression and that it also functions to help create a favorable tumor microenvironment. In this context, the renal cancer cell must develop mechanisms to escape the growth inhibitory effects of TGFb. Some have suggested that this escape may be mediated through alterations in the expression of TBR1, TBR2, and/or the Smads, yet the exact mechanism has not been described or rigorously tested. Based on our investigation, we hypothesize that this escape from the growth-inhibitory effects of TGFb is mediated through the stepwise sequential loss of TBR3 and TBR2 expression. To our knowledge, no one has linked sequential loss of TBR3 and TBR2 to carcinogenesis and metastatic progression in oncology. This is the first time that stepwise loss of a single transduction pathway has been associated with important biologic sequelae in a human cancer. Furthermore, our results suggest that the loss of each specific receptor coincides with a biologically relevant event in the host (i.e. carcinogenesis and metastasis). These findings are in stark contrast to TGFb signaling that remains intact and has been implicated in the development of chronic renal diseases resulting in renal fibrosis from glomerular and tubular epithelial cell apoptosis and cellular transdifferentiation to a mesenchymal cell type (Bottinger and Bitzer, 2002) . Fibrosis is not a common histologic finding in RCC. Thus, these two disease states present with elevated serum TGFb levels but are polar opposites, most likely due solely to differences in TBR expression that regulate sensitivity to TGFb (Wunderlich et al., 1998) .
With re-expression of TBRs in our laboratory models, we observed complete reconstitution of TGFb signaling relative to controls. This suggests that Smad expression and signaling function is not significantly altered in human RCC and that TGFb insensitivity must therefore be derived at the receptor level. This observation was further validated in our gene array data, which detected no significant difference in the expression of Smads between normal renal epithelium and RCC (data not shown).
The TGFb literature is replete with studies that implicate alterations in TBR1 and TBR2 expression in human cancers (reviewed in Akhurst and Derynck, 2001) . Interestingly, relatively little attention has been paid to TBR3 in TGFb signaling. TBR3 is not thought to possess signal transduction capacity, but instead is thought to facilitate TGFb ligand binding to TBR2 (Deng et al., 1999) . Recent studies have challenged this notion and suggested that TBR3 may participate in signal transduction independent of TBR2 through its cytoplasmic domain (Blobe et al., 2001; Boyer and Runyan, 2001) . Furthermore, overexpression of TBR3 alone in breast cancer cell lines significantly inhibited cell growth in vitro and in vivo Sun and Chen, 1997) . Our study demonstrates that loss of TBR3 expression is an early event in RCC biology and that this loss has important sequelae with regard to RCC carcinogenesis and progression. All our clinical samples of localized RCC demonstrated loss of TBR3, but had normal expression of TBR1 and TBR2. Replication of this clinical observation in our in vitro models demonstrated significant loss of TGFb sensitivity, manifest as a significant reduction in the growthinhibitory effects of TGFb1 and significantly reduced TGFb-mediated transcription. Interestingly, cell lines derived from localized RCC retained TBR2 expression and therefore, still demonstrated sensitivity, albeit reduced, to TGFb. Only with metastatic progression and loss of TBR2 expression does the cell become completely resistant to the effects of TGFb. We hypothesize that this retained, but attenuated, TGFb signaling seen in local tumors must convey some as yet unrecognized biologic benefit for local tumors that is no longer required, and therefore discarded, with metastatic progression. In fact, this loss of TBR2 expression may be an absolute integral component in the cascade of intracellular events that lead to the development of metastatic potential. In keeping with this hypothesis, Takahashi et al. (2001) showed that loss of TBR2 expression was one of 40 integral alterations of gene expression to predict for poor prognosis of patients diagnosed with RCC.
This study demonstrates a clear link between loss of TBR3 expression to a human disease state. Data from the Sun laboratory have demonstrated reduced TBR3 expression in human breast tumor cell lines, suggesting that loss of TBR3 expression may be a more ubiquitous phenomena in carcinogenesis, rather than an isolated finding in human RCC biology Sun and Chen, 1997) . The fact that we found downregulation of TBR3 in every RCC specimen studied to date (35 patients) and that re-expression of TBR3 (in the presence of re-expressed TBR2) completely abolish growth on soft agar suggests an important role for TBR3 in NRE homeostasis that must be abrogated for renal cell carcinogenesis and progression to occur. As stated earlier, little attention has been given to TBR3 in normal cell biology or the changes in expression that occur with carcinogenesis and progression. Our observations, and those of others, would suggest that TBR3 plays an important functional role in signaling and that loss of expression is an important event in the acquisition of the tumorigenic and metastatic phenotype in human RCC. Our data are the first to demonstrate an unambiguous link between loss of TGFb responsiveness and malignant transformation of renal epithelial cells, strongly suggesting that attenuation of TBR3 is a required step in RCC carcinogenesis. Previous studies have demonstrated that alterations in TGFb signaling are associated with tumor progression and metastasis, but these studies have not suggested that alterations in TGFb signaling occur as an early event in neoplastic transformation (Akhurst and Derynck, 2001) . Based on our data and the work of others, it is now becoming more evident that aberrations in TGFb signaling may be an early event in the natural history of cancer and not a late event (Allander et al., 2001) . How many other gene alterations in other critical signaling pathways are required for the neoplastic transformation of normal renal tubule epithelial cells to RCC remain to be determined, but our data suggest that loss of TBR3 expression is a critical early event in the natural history of sporadic RCC.
Materials and Methods
Tissue banking
On ice and under sterile conditions, renal tissue (normal and tumor) was transported to a sterile hood within the Pathology Department (CG Wood IRB protocol #LAB02-176). Tissue was dissected under the direction of a pathologist. The tissue was frozen in liquid nitrogen (isolation of RNA, DNA, and protein), processed to establish primary cell cultures, and tissue was fixed in formalin for immunohistochemistry and in situ hybridization and RNAlater (Ambion) for RNA isolation. Primary NRE cell cultures were established using standard collagenase/Dnase techniques to digest tissue and isolate single cells (Grossman et al., 1985) . NREs are easily isolated and grow well in culture for up to 10 passages. We have further analysed these cells for homogeneity with regard to epithelial population using appropriate immunohistochemical markers (vimentin, cytokeratin, and megalin; data not shown).
Genomic gene array and microarray data analysis methods
We have performed gene expression profiling using Affymetrix HU95A oligonucleotide gene arrays (412 600 genes). Total RNA (Trizol; Ambion) was extracted from patient-matched normal renal cortex and tumor tissue from patients diagnosed with local disease confined to the kidney. Alternatively, we have analysed metastatic disease, defined by lesions in lymph nodes, adrenal, or other organs. Data were analysed by a combination of two-dimensional ANOVA, Affymetrix MAS5.0, and hierarchical cluster analysis using Spotfire. Space precludes a detailed description of the procedure that we have used to identify altered expression of large sets of genes, as well as other issues concerning microarray analyses; but a thorough consideration can be found in our recent review article on this subject (Copland et al., 2003) .
Cell proliferation assay
UMRC6 and UMRC3 RCC tumor cell lines were a kind gift from Dr Bart Grossman (Grossman et al., 1985) . DNA content of cells was used as a measure of cell proliferation. Cells were plated at 20 000 cells/well in 12-well plates. Cells were grown in 10% FBS : DMEM : penicillin : streptomycin. The following day, media were exchanged with the appropriate treatment added to the media. On day 3 of treatment, cells were analysed for DNA content using Hoechst reagent. DNA standard was used to correlate DNA content per well.
TGFb-mediated transcriptional reporter assay
Transcriptional response to TGFb treatment was determined by transiently transfecting 3TP/lux (gift Dr Joan Massague) along with SV/renilla luciferase (Promega) into cells using fugene (Roche) as the transfection agent. Cells were treated 7TGFb1 after 24 h of transfection and luciferase activity (Promega Luciferase Assay system and Lumat luminometer) was determined 24 h after TGFb treatment. Firefly luciferase activity was normalized using the ratio of firefly luciferase/ renilla luciferase.
Real-time PCR
Applied Biosystems' assays-by-design or assays-on-demand 20 Â assay mix of primers and TaqMan MGB probes (FAMt dye-labeled) for all our target genes and predeveloped 18S rRNA (VICt-dye labeled probe) TaqMan s assay reagent (P/ N 4319413E) for internal control were used for real-time PCR measurements. These assays were designed to span exon-exon junctions so as not to detect genomic DNA and all primers and probe sequences were searched against the Celera database to confirm specificity. Validation experiments were performed to test the efficiency of the target amplification and the efficiency of the reference amplification. All absolute values of the slope of log input amount versus DC T is less than 0.1. Separate tubes (singleplex) for one-step RT-PCR was performed with 50ng RNA for both target genes and endogenous controls using TaqMan one-step RT-PCR master mix reagent kit (Applied Biosystems). The cycling parameters for one-step RT-PCR were: reverse transcription 481C for 30 min, AmpliTaq activation 951C for 10 min, denaturation 951C for 15 s, and annealing/extension 601C for 1 min (repeat 40 times) on ABI7000. Duplicate C T values were analysed with Microsoft Excel using the comparative C T (DC T ) method as described by the manufacturer (Applied Biosystems). The amount of target (2 ÀDDCT ) was obtained by normalizing to an endogenous reference (18smRNA) and relative to a calibrator (normal tissue).
Immunohistochemical analyses of protein expression
For immunohistochemical analyses of TBR1, TBR2, and TBR3 expression, patient-matched normal renal and tumor tissue samples were fixed in 10% neutral-buffered formalin and embedded in paraffin blocks. Consecutive sections were cut 5 mm thick, deparaffinized, hydrated, and immunostained using antibodies recognizing human TBR1, TBR2, and TBR3 (1 : 100; Santa Cruz Biotechnology). Biotinylated secondary antibody (1 : 600; Santa Cruz Biotechnology) was detected using avidin-biotin-peroxidase detection according to the manufacturer's instructions (Vectastatin Elite ABC kit; Vector Lab). All slides were lightly counterstained with hematoxylin before dehydration and mounting. For cell lines, cells were plated on glass coverslips in wells. Prior to the detection of TBR expression as described above, cells were fixed onto the coverslips with 3% formalin.
Plasmid construction and transfections
Expression vector containing the complete coding sequences for human TBR2 (a gift from Dr K Miyazono; TBR2 cloned into EcoRI/XbaI site of pcDNA3/FLAG) was stably transfected into UMRC3 cells using fugene as the DNA carrier and genticin as the selection antibiotic (Sigma, 1 mg/ml). Ten clones (UMRC3/TBR2) were selected and verified for TBR 2 mRNA and protein (e.g. Western analysis using the FLAG antibody) expression (data not shown). From these cell clones, one was selected that had equivalent protein expression of TBR2 to that of NRE and UMRC6 cells to then transfect the TBR3 expression vector stably. The TBR3 coding sequence was PCR amplified from a plasmid expressing wild-type TBR3 in pSV7d (a gift from Dr C-H Heldin). TBR3 was then cloned into the EcoRI site in the sense and antisense (negative control) orientation of pcDNA4/TO/myc-His & (InVitrogen). The orientation and sequence of TBR3 was verified. The antisense TBR3 (As TBR3) vector was used as a control. TBR3/ pcDNA4/TO/myc-His and As TBR3/pcDNA4/TO/myc-His vectors were stably transfected into UMRC3/TBR2 cells. A clone was selected that demonstrated an equivalent expression of TBR3 mRNA to that of NRE cells. As a control for UMRC3 þ TBR2 and UMRC3 þ TBR2 þ TBR3, wild-type UMRC3 were stably transfected with both pcDNA/FLAG and pcDNA4/TO/myc-His vectors.
Colony formation assay
Either UMRC3 (pcDNA/FLAG and pcDNA4/T0/myc-His empty vectors), UMRC3 þ TBR2, or UMRC3 þ TBR2 þ TBR3 cells were plated at 1000 cells/60 mm dish in an agarose/FBS/media sandwich in the presence of 2 ng/ml TGFb. No selection antibodies were added to the agarose media mixture. Typically, cells are incubated for 2-3 weeks; however, we incubated cells for 45 days to insure that no colony formation would occur. Cells were then stained with 0.005% Crystal Violet, photographed, and assessed for number and size of colonies.
Statistics
ANOVA followed by the Newman-Keuls test were used to determine statistical differences between the means of treatment groups. Differences were considered to be significant at Po0.05 level. Values represent the mean7s.e. of three experiments carried out in triplicate.
Abbreviations RCC, renal cell carcinoma; TGFb, transforming growth factor b; TBR3, type III TGFb receptor; TBR2, type II TGFb receptor; TBR1, type I TGFb receptor.
